Eisai Receives Marketing Approval for Zonegran® (zonisamide) Monotherapy Treatment for Epilepsy (y 2)

Actualizado 03/07/2012 3:02:45 CET

With operations in the U.S., Asia, Europe and its domestic home market of Japan, Eisai employs more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Slovakia, Slovenia, the Netherlands, and Belgium. For further information please visit our web site http://www.eisai.com References 1. Eisai Ltd 2012. Zonegran Summary of Product Characteristics

2. St. Louis, K. Rosenfeld. W. Bramley, T. Antiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management (2009) &(2): 77 - 72

3. ILAE/IBE/WHO, Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe 2010. Available from; http://www.ilae-epilepsy.org/Visitors/Documents/EUROReport160510.pdf (Accessed June 2011)

4. Epilepsy Society UK: http://www.epilepsysociety.org.uk/AboutEpilepsy/Whatisepilepsy/Epilepsy-didyouknow (Accessed June 2011)

5. Baulac, M. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurology (2012), 3 Jul. (7) - 579 - 588

6. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224 - 2233

Date of preparation: July 2012

Job code: Zonegran-UK2444

CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson,+44(0)7908-314-155, Cressida_Robson@eisai.net; Tonic Life Communications,Benjamyn Tan / Leah Peyton, +44(0)207-798-9262 / +44(0)7792-034-191,benjamyn.tan@toniclc.com / leah.peyton@toniclc.com

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación